April 2026 in “Dermatology and Therapy” This study reviews the efficacy and safety of advanced therapies like TNFα inhibitors and IL-17/IL-23 inhibitors for dissecting cellulitis of the scalp, finding TNFα inhibitors particularly effective for severe or refractory cases, although prospective validation is needed for early intervention benefits.
2 citations
,
April 2025 in “Biologics” This study reviewed clinical trials and reports on cytokine-targeting biologics for alopecia areata, finding Dupilumab and Ustekinumab showed strong efficacy, while other biologics had limited success or worsened the condition. Further research is needed to optimize biologic therapies for AA.
8 citations
,
July 2024 in “Children” This study discusses how emerging biologics and small molecule therapies could enhance disease management and pediatric health outcomes for chronic skin conditions, suggesting their potential inclusion in treatment guidelines pending ongoing clinical trial successes.
12 citations
,
December 2010 in “Journal of thoracic oncology” This article organizes and lists ongoing and completed clinical trials of novel agents for lung cancer, serving as a reference tool with no new research findings reported.
1 citations
,
October 2024 in “QJM” This study compared the long-term efficacy and safety of biologics targeting TNF alpha and IL-12/23 in moderate to severe psoriasis, finding that IL-12/23 inhibitors were more effective at achieving a PASI 75 response, while both treatments showed a similar risk of serious infection and malignancy.
